OncoMatch/Clinical Trials/NCT06389760
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Is NCT06389760 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nimotuzumab and mFOLFIRINOX for pancreatic cancer.
Treatment: Nimotuzumab · mFOLFIRINOX · GX — This is a prospective, multicenter, single-arm, open-label study. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX/GX for postoperative adjuvant treatment of pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Prior systemic anti-tumor therapy, such as chemotherapy, radiotherapy
Lab requirements
Blood counts
White blood cells (WBC) ≥ 3.0×10^9/L; absolute neutrophil count (ANC) ≥ 1.5×10^9/L; hemoglobin ≥ 9.0 g/dL; platelets ≥ 75×10^9/L
Kidney function
serum creatinine ≤ 1×ULN or estimated creatinine clearance ≥ 50 mL/min
Liver function
serum total bilirubin (TBIL) ≤ 1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Adequate organ and bone marrow function, defined as follows: White blood cells (WBC) ≥ 3.0×10^9/L; absolute neutrophil count (ANC)≥1.5×10^9/L; hemoglobin≥9.0 g/dL; platelets≥75×10^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1×ULN or estimated creatinine clearance ≥ 50 mL/min; Left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify